Physician profile
Huy Tran
NPI 1699082149
$897.73
in general payments reported to CMS, 2019-2025
21 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $243 · 2024: $365 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.57 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.53 | 2023-2025 | Linzess, Viberzi, Creon |
| Coloplast Corp | $172.90 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $121.29 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $85.90 | 2023-2024 | Dupixent |
| Genzyme Corporation | $76.83 | 2023 | |
| Enterra Medical, INC. | $66.98 | 2023-2025 | |
| Qol Medical, LLC | $39.19 | 2024 | Sucraid |
| Dentsply Ih Ab | $27.86 | 2024 | Navina Rectal Catheter Set Regular |
| Braintree Laboratories, INC. | $25.03 | 2024 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.56 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $21.30 | 2024 | Eohilia |
| Endogastric Solutions, INC | $18.04 | 2024 | Esophyx |
| Lucid Diagnostics INC. | $15.32 | 2024 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.